IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

被引:49
作者
Zhou, C. [1 ]
Das Thakur, M. [2 ]
Srivastava, M. K. [2 ]
Zou, W. [3 ]
Xu, H. [4 ]
Ballinger, M. [5 ]
Felip, E. [6 ]
Wakelee, H. [7 ]
Altorki, N. K. [8 ]
Reck, M. [9 ]
Liersch, R. [10 ]
Kryzhanivska, A. [11 ]
Harada, M. [12 ]
Tanaka, H. [13 ]
Hamm, J. [14 ]
McCune, S. [15 ]
McNally, V. [16 ]
Bennett, E. [5 ]
Gitlitz, B. [17 ]
Novello, S. [18 ]
机构
[1] Tongji Univ, Dept Med Oncol, Affiliated Shanghai Pulm Hosp, Shanghai, Peoples R China
[2] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA
[3] Genentech Inc, Prod Dev Data Sci, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, Prod Dev Data Sci, Mississauga, ON, Canada
[5] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[6] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Oncol, Barcelona, Spain
[7] Stanford Univ, Sch Med, Med Oncol, Stanford Canc Inst, Stanford, CA 94305 USA
[8] NewYork Presbyterian Hosp, Weill Cornell Med, Cardiothorac Surg, New York, NY USA
[9] German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Thorac Oncol, Grosshansdorf, Germany
[10] Clemenshosp Munster, Oncol, Munster, Germany
[11] Ivano Frankivsk Natl Med Univ, Gynecol Surg Dept, Ivano Frankivsk, Ukraine
[12] Hokkaido Canc Ctr, Resp Med, Sapporo, Hokkaido, Japan
[13] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
[14] Norton Canc Inst, Med Oncol, Louisville, KY USA
[15] Northwest Georgia Oncol Ctr, Res, Marietta, GA USA
[16] Roche Prod Ltd, Clin Dev, Welwyn Garden City, Herts, England
[17] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA
[18] Univ Turin, Oncol, AOU San Luigi Gonzaga, Orbassano, Italy
关键词
D O I
10.1016/j.annonc.2021.10.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
20
引用
收藏
页码:S1374 / S1374
页数:1
相关论文
empty
未找到相关数据